Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 203

The DOI matches its Crossref record.

Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice

Stewart, Clinton F., Leggas, Markos, Schuetz, John D., Panetta, John C., Cheshire, Pamela J., Peterson, Jennifer, Daw, Najat, Jenkins, Jesse J., Gilbertson, Richard, Germain, Glen S., Harwood, Franklin C., Houghton, Peter J.·2004·Cancer Research

Abstract

As a single agent the ERBB1 inhibitor, gefitinib (Iressa; ZD1839) showed minimal activity against a panel of 10 pediatric tumor xenografts that do not express the ERBB1 receptor. However, combined with irinotecan (CPT-11), significantly greater than additive activity was observed in four of eight models (P < 0.05), and the combination showed enhanced activity against three additional tumor lines. Breast cancer resistance protein (ABCG2), a transporter that confers resistance to SN-38 (the active metabolite of irinotecan), was readily detected in six of nine xenograft models examined by immunohistochemistry. In vitro gefitinib potently reversed resistance to SN-38 only in a cell line that overexpressed functional ABCG2. However, overexpression of ABCG2 did not decrease accumulation nor increase the rate of efflux of [14C]gefitinib. On the basis of these results and the distribution of Abcg2 in mouse tissues, we assessed the ability of gefitinib to modulate irinotecan pharmacokinetics. Oral gefitinib coadministration resulted in no change in clearance of intravenously administered irinotecan. However, gefitinib treatment dramatically increased the oral bioavailability of irinotecan after simultaneous oral administration. It is concluded that gefitinib may modulate SN-38 activity at the cellular level to reverse tumor resistance mediated by ABCG2 through inhibiting drug efflux and may be used potentially in humans to modulate the oral bioavailability of a poorly absorbed camptothecin such as irinotecan.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-04-0096

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 203

Metadata

Authors
Stewart, C. F., Leggas, M., Schuetz, J. D., Panetta, J. C., Cheshire, P. J., Peterson, J., Daw, N., Jenkins, J. J., Gilbertson, R., Germain, G. S., Harwood, F. C., & Houghton, P. J.
Venue
Cancer Research
Published
2004-10-15
Volume
64
Issue
20
Pages
7491-7499
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2156609950
Cited by
203
References
0
FWCI
7.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-0096
The paper
Stewart, C. F., Leggas, M., Schuetz, J. D., Panetta, J. C., Cheshire, P. J., Peterson, J., Daw, N., Jenkins, J. J., Gilbertson, R., Germain, G. S., Harwood, F. C., & Houghton, P. J. (2004). Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-0096

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.